Sanjivani Parenteral Limited delivered impressive financial performance in Q1 FY27, with consolidated net profit rising 43.94% to ₹24.91 crore compared to ₹17.30 crore in the corresponding quarter of the previous year. According to the company's latest unaudited financial results announced on August 14, this significant profit growth demonstrates the company's operational efficiency and market positioning during the quarter. PAT margin improved to 10.38% during the quarter, reflecting enhanced profitability metrics.
The company's total income registered a robust 33.81% YoY growth in Q1 FY27, indicating strong demand for the company's products and services. As reported in the company's latest financial results, this substantial revenue growth was complemented by healthy financial performance across all business segments. The company's sales revenue increased 33.26% to ₹23.84 crore in Q1 FY2026, up from ₹17.89 crore in the same period last year, showing consistent growth momentum.
EBITDA increased 61.04% YoY to ₹43.21 crore in Q1 FY27, with EBITDA margin improving by 305 basis points to 18.01%, reflecting significantly enhanced operating efficiencies. According to the company's management commentary, this margin expansion was driven by improved cost management, operational efficiency, and stronger business performance. Operating profit margin (OPM) improved to 17.49% in the June 2026 quarter, compared to 14.76% in the corresponding quarter of the previous year, demonstrating sustained operational excellence.
According to latest market analysis, Sanjivani Parenteral Limited is trading at a Price-To-Earnings ratio of 32.1x, which is considered expensive compared to the peer average of 27.6x in the IN Pharmaceuticals Industry. However, the company is trading below its estimated Fair Price-To-Earnings Ratio of 43.8x, suggesting it may be undervalued relative to future earnings growth. The stock has shown significant price movements with a 5-year high of ₹940.00 and 5-year low of ₹601.00, reflecting strong investor interest in the company's growth prospects.
Commenting on the performance, Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Parenteral Limited, highlighted that Q1 FY27 was marked by a positive start supported by recovery in exports and continued operational focus. As reported in the company's press release, he noted that the Pune IV Fluid facility is witnessing gradual scale-up with increasing commercialization and customer traction, while the core formulations business remains resilient. The management expressed focus on strengthening manufacturing capabilities, expanding product portfolio, and enhancing presence across domestic and international markets.
Looking ahead, the company remains focused on leveraging improving operational efficiencies, growing customer traction, and market opportunities to drive sustainable growth and create long-term value for stakeholders. According to the management commentary, the company will continue to focus on enhancing manufacturing capabilities, improving efficiencies, and expanding business presence across key markets. For FY26, the company had reported Total Income of ₹697.56 crore, EBITDA of ₹114.00 crore, and PAT of ₹66.94 crore on a consolidated basis, providing a strong foundation for continued growth.
